English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Background Diarrhoea is a common complication seen in renal transplant recipients. Post-transplantation diarrhoea may result from infectious agents, drug-specific effects or metabolic conditions. Although infections are the major cause of diarrhoea after transplantation, almost a quarter of the cases are related to medication. Approximately 50% of the drug-induced diarrhoea is caused by mycophenolate mofetil (MMF) [1]. MMF is a commonly used immunosuppressive agent that can induce ulcerating colitis [2,3]. MMF-induced ulceratingcolitis isadiagnosisbyexclusion. The pathological diagnosis is difficult because of the similarities with other causes of diarrhoea such as inflammatory bowel disease [4]. Although MMF-induced colitis usually resolves after dose reduction or cessation of MMF, persistent cases havebeen reported [5]. We present a case in which MMF-induced ulcerating colitis persisted after withdrawal of MMF but was successfully treated with tumour necrosis factor-alpha (TNF-α) inhibition.

Rapid resolution of persistent mycophenolate mofetil-induced diarrhoea with a single dose of infliximab